Drugs in R & D

, Volume 3, Issue 2, pp 87–103 | Cite as

Efficacy of N-Acetylcarnosine in the Treatment of Cataracts

  • Mark A. Babizhayev
  • Anatoly I. Deyev
  • Valentina N. Yermakova
  • Yuri A. Semiletov
  • Nina G. Davydova
  • Valerii S. Doroshenko
  • Alexander V. Zhukotskii
  • Ita M. Goldman
Original Research Article


Purpose: To evaluate the effects of 1%N-acetylcarnosine (NAC) solution on lens clarity over 6 and 24 months in patients with cataracts.

Trial design: Randomised, placebo-controlled study.

Participants: 49 subjects (76 affected eyes) with an average age of 65.3 ± 7.0 years with a diagnosis of senile cataract with minimum to advanced opacification in various lens layers.

Methods: 26 patients (41 eyes)were allocated to topicalNAC 1% eyedrops twice daily. The control group consisted of 13 patients (21 eyes) who received placebo eyedrops and 10 patients (14 eyes) who did not receive eyedrops.

Main outcome measures: All patients were evaluated at entry and followed up every 2 months for a 6-month period (trial 1), or at 6-month intervals for a 2-year period (trial 2), for best-corrected visual acuity and glare testing. In addition, cataract was measured using stereocinematographic slit-images and retro-illumination examination of the lens. Digital analysis of lens images displayed light scattering and absorbing centres in two- and three-dimensional scales.

Results: The overall intra-reader reproducibility of cataract measurements (image analysis) was 0.830, and glare testing 0.998. After 6 months, 90% of NAC-treated eyes showed improvement in best corrected visual acuity (7 to 100%) and 88.9% showed a 27 to 100% improvement in glare sensitivity. Topographic studies indicated fewer areas of posterior subcapsular lens opacity and 41.5% of treated eyes had improvement in image analysis characteristics. The overall ratios of image analysis characteristics at 6 months compared with baseline measures were 1.04 and 0.86 for the control and NAC-treated group, respectively (p < 0.001). The apparent benefits of treatment were sustained after 24 months’ treatment. No treated eyes demonstrated worsening of vision. The overall visual outcome in the control group showed significant worsening after 24 months in comparison with both baseline and the 6-month follow-up examination. The overall clinical results observed in the NAC-treated group by the 24-month period of examination differed significantly (p < 0.001) from the control group in the eyes with cortical, posterior subcapsular, nuclear or combined lens opacities.

Tolerability of NAC eyedrops was good in almost all patients, with no reports of ocular or systemic adverse effects.

Conclusion: Topical NAC shows potential for the treatment and prevention of cataracts.


Visual Acuity Cataract Carnosine Lens Image Lens Opacity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was organised, conducted and supported by Innovative Vision Products, Inc, County of New Castle, Delaware, USA.


  1. 1.
    World Health Organization. Management of cataract in primary health care services. Geneva, 1990: WHOGoogle Scholar
  2. 2.
    Kupfer C, Underwood B, Gillen T. Leading causes of visual impairment worldwide. In: Albert DM, Jakobiec FA, editors. Principles and practice of ophthalmology. Basic Sci. Philadelphia: W.B. Saunders & Co, 1994: 1249–1255Google Scholar
  3. 3.
    Spector A. Review: oxidative stress and disease. J Ocul Pharmacol Ther 2000; 16: 193–201PubMedCrossRefGoogle Scholar
  4. 4.
    Vision Research, ANational Plan 1999–2002. Report of the National Advisory Council, National Eye Institute, 1998: 59Google Scholar
  5. 5.
    Stark WJ, Sommer A, Smith RE. Changing trends in intraocular lens implantation. Arch Ophthalmol 1989; 107: 1441–4PubMedCrossRefGoogle Scholar
  6. 6.
    Kupfer C. The conquest of cataract, a global challenge. Trans Ophthalmol Soc UK 1984; 104: 1–10Google Scholar
  7. 7.
    Dische Z, Zil H. Studies on the oxidation of cysteine and cystine in lens proteins during cataract formation. Am J Ophthalmol 1951; 34: 104–13PubMedGoogle Scholar
  8. 8.
    Spector A, Roy D. Disulfide-linked high molecular weight protein associated with human cataract. Proc Natl Acad Sci USA 1978; 75: 3244–8PubMedCrossRefGoogle Scholar
  9. 9.
    Garner MH, Spector A. Selective oxidation of cysteine and methionine in normal and senile cataractous lenses. Proc Natl Acad Sci USA 1980; 77: 1274–7PubMedCrossRefGoogle Scholar
  10. 10.
    Augusteyn RC. Protein modification in cataract: possible oxidative mechanisms. In: Duncan G, editor. Mechanisms of cataract formation in human lens. New York: Academic Press, 1981: 72–115Google Scholar
  11. 11.
    Varma SD, Chand D, Sharma YR, et al. Oxidative stress on lens and cataract formation: role of light and oxygen. Curr Eye Res 1984; 3: 35–57PubMedCrossRefGoogle Scholar
  12. 12.
    Bhuyan KC, Bhuyan DK. Molecular mechanism of cataractogenesis: III. Toxic metabolites of oxygen as mediators of lipid peroxidation and cataract. Curr Eye Res 1984; 3: 67–81PubMedCrossRefGoogle Scholar
  13. 13.
    Babizhayev MA, Deyev AI, Linberg LP. Lipid peroxidation as a possible cause of cataract. Mech Ageing Dev 1988; 44: 69–89PubMedCrossRefGoogle Scholar
  14. 14.
    Zigman S. Photochemical mechanisms in cataract formation. In: Duncan G, editor. Mechanisms of cataract formation in human lens. London: Academic Press, 1981: 117–149Google Scholar
  15. 15.
    Spector A, Garner W. Hydrogen peroxide and human cataract. Exp Eye Res 1981; 33: 673–81PubMedCrossRefGoogle Scholar
  16. 16.
    Varma SD. Superoxide and lens of the eye: a new theory of cataractogenesis. Int J Quantum Chem 1981; 20: 479–84CrossRefGoogle Scholar
  17. 17.
    Babizhayev MA, Deyev AI. Lens opacity induced by lipid peroxidation products as a model of cataract associated with retinal disease. Biochim Biophys Acta 1989; 1004: 124–33PubMedCrossRefGoogle Scholar
  18. 18.
    Babizhayev MA, Bozzo Costa E. Lipid peroxide and reactive oxygen species generating systems of the crystalline lens. Biochim Biophys Acta 1994; 1225: 326–37PubMedCrossRefGoogle Scholar
  19. 19.
    Robertson JM, Donner AP, Trevithick JR. A possible role for vitamins C and E in cataract prevention. Am J Clin Nutr 1991; 53: 346S–51SPubMedGoogle Scholar
  20. 20.
    Borchman D, Paterson CA, Delamere NA. Oxidative inhibition of Ca2+-ATPase in the rabbit lens. Invest Ophthalmol Vis Sci 1989; 30: 1633–7PubMedGoogle Scholar
  21. 21.
    Babizhayev MA, Deyev AI. Free radical oxidation of lipids and thiol groups in genesis of cataract. Biophysics 1986; 31: 119–25Google Scholar
  22. 22.
    Babizhayev MA. Lipid fluorophores of the human crystalline lens with cataract. Graefes Arch Clin Exp Ophthalmol 1989; 227: 384–91PubMedCrossRefGoogle Scholar
  23. 23.
    Babizhayev MA, Seguin M-C, Gueyne J, et al. L-Carnosine (β-alanyl-L-histidine) and carcinine (β-alanylhistamine) act as natural antioxidantswith hydroxyl radicals scavenging and lipid peroxidase activities. Biochem J 1994; 304: 509–16PubMedGoogle Scholar
  24. 24.
    Dahl TA, Midden WR, Hartman PE. Some prevalent biomolecules as defenses against singlet oxygen damage. Photochem Photobiol 1988; 47: 357–62PubMedCrossRefGoogle Scholar
  25. 25.
    Boldyrev AA, Dupin AM, Bunin AYa, et al. The antioxidative properties of carnosine, a natural histidine containing dipeptide. Biochem Int 1987; 15: 1105–13PubMedGoogle Scholar
  26. 26.
    Babizhayev MA. Antioxidant activity of L-carnosine, a natural histidine-containing dipeptide in crystalline lens. Biochim Biophys Acta 1989; 1004: 363–71PubMedCrossRefGoogle Scholar
  27. 27.
    Jackson MC, Kucera CM, Lenney JF. Purification and properties of human serum carnosinase. Clin Chim Acta 1991; 196: 193–206PubMedCrossRefGoogle Scholar
  28. 28.
    O’Dowd JJ, Robins DJ, Miller DJ. Detection, characterization, and quantification of carnosine and other histidyl derivatives in cardiac and skeletal muscle. Biochim Biophys Acta, 1988; 967: 241–9PubMedCrossRefGoogle Scholar
  29. 29.
    Okabe S, Ainehara T, Sato M, et al. Pharmaceuticals containing N-acetylcarnosine aluminium salt for treatment of gastric ulcer. Japanese Patent Nippon Chemiphar Co. Ltd. Jpn Kokai Tokkyo Koho JP 62 84, 063 [87,84,063] (Cl. C07D 233/64) 17 Apr. 1987, Appl. 86/215,196 12 Sept 1986, 7 pp. Chem Abstr 1987; 107: 223–279Google Scholar
  30. 30.
    Anderson JA, Davis WL, Wei C. Site of ocular hydrolysis of a prodrug, dipivefrin, and a comparison of its ocular metabolism with that of the parent compound, epinephrine. Invest Ophthalmol Vis Sci 1980; 19: 817–23PubMedGoogle Scholar
  31. 31.
    Babizhayev MA, Yermakova VN, Sakina NL, et al. NAcetylcarnosine is a prodrug of L-carnosine in ophthalmic application as antioxidant. Clin Chim Acta 1996; 254: 1–21PubMedCrossRefGoogle Scholar
  32. 32.
    Babizhayev MA, Bozzo Costa E. Composizioni farmaceutiche contenentiN-acetilcarnosina per il trattamento della cataratta. Italian Patent A61K gruppo 37/00 20122 MI, Priority Oct 15 1993Google Scholar
  33. 33.
    Babizhayev MA, Bozzo Costa E. Pharmaceutical compositions containing N-acetylcarnosine for the treatment of cataract. Patent PCT/EP 94/03340 SCB 238 PCT, Oct 10 1994Google Scholar
  34. 34.
    Babizhayev MA, Yermakova VN, Deyev AI, et al. Imidazolecontaining peptidomimetic NACA as a potent drug for the medicinal treatment of age-related cataract in humans. JAnti-Aging Med 2000; 3: 43–62PubMedCrossRefGoogle Scholar
  35. 35.
    Babizhayev MA, Deyev AI, Yermakova VN, et al. N-Acetylcarnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts. Peptides 2001; 22: (6): 979–94PubMedCrossRefGoogle Scholar
  36. 36.
    Babizhayev MA, Zhukotskii AV, Sologub AA. Image analysis of the lens opacities induced in developing chick embryo by glucocorticoid. Exp Eye Res 1992; 55: 521–37PubMedCrossRefGoogle Scholar
  37. 37.
    Babizhayev MA, Deyev AI, Derevyagin VI. Morphometric evaluation of human lens opacification. J Microsc 1989; 154: 115–27PubMedCrossRefGoogle Scholar
  38. 38.
    West SK. Daylight, diet, and age-related cataract. Optom Vis Sci 1993; 70: 869–72PubMedCrossRefGoogle Scholar
  39. 39.
    Yager D, Yuan R, Mathews S. What is the utility of the psychophysical “light scattering factor”? Invest Ophthalmol Vis Sci 1992; 33: 688–90PubMedGoogle Scholar
  40. 40.
    Babizhayev MA. Failure to withstand oxidative stress induced by phospholipid hydroperoxides as a possible cause of the lens opacities in systemic diseases and ageing. Biochim Biophys Acta 1996; 1315: 87–99PubMedCrossRefGoogle Scholar
  41. 41.
    Babizhayev MA, Yermakova VN, Semiletov YA, et al. The natural histidine-containing dipeptide N-acetylcarnosine as an antioxidant for ophthalmic use. Biochemistry (Moscow) 2000; 65:588–98Google Scholar
  42. 42.
    Babizhayev MA, Bunin AYa. Lipid peroxidation in open-angle glaucoma. Acta Ophthalmol (Copenh) 1989; 67: 371–7CrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Mark A. Babizhayev
    • 1
    • 2
  • Anatoly I. Deyev
    • 1
  • Valentina N. Yermakova
    • 2
  • Yuri A. Semiletov
    • 1
  • Nina G. Davydova
    • 2
  • Valerii S. Doroshenko
    • 1
  • Alexander V. Zhukotskii
    • 1
  • Ita M. Goldman
    • 1
  1. 1.Innovative Vision Products, Inc.County of NewcastleUSA
  2. 2.Moscow Helmholtz Research Institute of Eye DiseasesMoscowRussia

Personalised recommendations